Cigna

Texnik xulosa

Indikator	Qiymat	Trend

Indikator	Qiymat	Trend

Indikator	Qiymat	Trend

Indikator	S3	S2	S1	P	R1	R2	R3

Yangiliklar

Reuters - 1 kun oldin

Some health insurers gain, others fall as Trump elected US president

BUZZ-Some health insurers gain, others fall as Trump elected US president Updates ** Shares of U nitedHealth UNH.N and Humana HUM.N rise 5.45% and 8.1%, respectively, as Donald Trump elected as U.S. president for a second term ** A Trump administration definitely increases the optimism and possibility of M&A happening in managed care companies, Bai

Reuters - 1 kun oldin

Some health insurers gain, others fall as Trump elected US President

BUZZ-Some health insurers gain, others fall as Trump elected US President Updates ** Shares of U nitedHealth UNH.N and Humana HUM.N rise 6% and 9%, respectively, in early trading on Wednesday as Donald Trump elected for a second term as US President * * Leerink analysts said a Trump presidency is "perceived less negative to positive" for insurers like UNH and HUM that serve Medicare Advantage plans for people 65 years and older ** "That too may be not be case, as we don't necessarily think Trump

Reuters - 2 kun oldin

Some health insurers gain, others fall as Trump elected US President for second term

BUZZ-Some health insurers gain, others fall as Trump elected US President for second term ** Shares of some U.S health insurers gain between 3% and 8% in premarket trade after Donald Trump elected U.S. president for a second term ** Humana HUM.N up 7.6%, while UnitedHealth UNH.N rises 6%, Cigna CI.N up 3.5% and Elevance ELV.N gains 3.3% before the bell ** J.P.

Reuters - 3 kun oldin

U.S. Celanese Corporation, Disc Medicine, Editas Medicine

U.S. RESEARCH ROUNDUP-Celanese Corporation, Disc Medicine, Editas Medicine Nov 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Celanese Corporation, Disc Medicine and Editas Medicine, on Tuesday. HIGHLIGHTS * Affiliated Managers Group Inc AMG.N : TD Cowen cuts to hold from buy * Celanese Corporation CE.N : Wells Fargo cuts to equal weight from overweight * Disc Medicine Inc IRON.O : Raymond James raises to strong b

Reuters - 3 kun oldin

GoodRx, PBMs accused of suppressing reimbursements to independent pharmacies

GoodRx, PBMs accused of suppressing reimbursements to independent pharmacies By Brendan Pierson Nov 4 (Reuters) - Drug coupon aggregator GoodRx and pharmacy benefit managers including CVS Caremark CVS.N and Express Scripts have been hit with at least three class action lawsuits accusing them of working together to suppress reimbursements to small pharmacies for generic prescription drugs.

Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.